EDAP EDAP TMS SA

EDAP TMS Announces That HIFU With Ablatherm Offers a Unique Curative Option for Radiotherapy Failures of Localized Prostate Cancer VAULX-EN-VELIN, France, June 14 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases, today announced that its High Intensity Focused Ultrasound ("HIFU") with Ablatherm can offer a salvage therapy to patients suffering from local recurrent prostate cancer after external beam radiotherapy failure. The Urology Department of Edouard Herriot Hospital ("HEH") in Lyon, France, has been a pioneer in the treatment of local recurrent prostate cancer after failed radiotherapy. A recent article by Dr. Albert Gelet of HEH. and Dr. Guy Vallancien of Institut Mutualiste Monsouris -- ("IMM") in Paris, published in Urology, reported that 71 patients, who initially showed indications of recurrent prostate cancer after radiotherapy, were treated using HIFU with Ablatherm. The conclusion of this article showed very satisfactory results with 80% negative biopsies, with up to seven years follow-up and low side effects in this population. Dr. Albert Gelet, Head of the Department of Urology at HEH, commented, "The population of patients who have a relapse of their localized prostate cancer after a radiotherapy treatment generally have very limited therapeutic options. This study shows that HIFU is a promising salvage treatment option for these patients with proven local recurrence after external beam and allows them to have a high local control rate of their disease." Pr. Guy Vallancien, Head of Department of Urology, I.M.M., Paris, added: "Clinical results obtained on patients with recurrent prostate cancer after external radiotherapy failure are very encouraging. It demonstrates that Ablatherm treatment using HIFU is now possible and shows positive outcomes with acceptable side effects for this pathology." Hugues de Bantel, President of the HIFU division commented: "We are very exited that this article confirmed the clinical interest of HIFU in managing this problematic pathology. Additionally, clinical trials are being carried out on patients suffering for recurrent prostate cancer after failed brachytherapy. The preliminary results are very promising and, if confirmed, could also lead to a huge potential for HIFU with Ablatherm, in the treatment of brachytherapy failures. The potential is particularly large for the US market where the number of patients treated with brachytherapy are higher that those undergoing surgery, and where the first relapses of cancer after brachytherapy begin to appear. We will work closely with our US partner HealthTronics to bring HIFU technology to these patients." EDAP TMS S.A. is the global leader in the development, production, marketing and distribution of a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The Company currently develops and markets devices for the minimally invasive treatment of localized prostate cancer, using High Intensity Focused Ultrasound (HIFU), through its EDAP SA subsidiary; it is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL), via its TMS SA subsidiary. In addition, the Company markets in Japan and Italy devices for the non-surgical treatment of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). For more information, in the U.S., contact EDAP Technomed Inc., the Company's U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950. For additional information on the Company, please see the Company's web site at: http://www.edap-tms.com/ . This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. CONTACT: Philippe Chauveau / Blandine Confort 33.4.72.15.31.50 Ian Vawter - EDAP Technomed Inc. 1.770.446.9950 DATASOURCE: EDAP TMS S.A. CONTACT: Philippe Chauveau, or Blandine Confort, +33-4-72-15-31-50; or Ian Vawter of EDAP Technomed Inc., +1-770-446-9950 Web site: http://www.edap-tms.com/

Copyright